



1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of :  
Donald L. Durden : Examiner: Not Yet Assigned  
: Group Art Unit: 1641  
Serial No. 10/770,725 :  
: Filed: February 3, 2004 :  
For: "COMPOSITIONS AND METHODS:  
FOR IDENTIFYING AGENTS :  
WHICH MODULATE PTEN :  
FUNCTION AND PI-3 KINASE :  
PATHWAYS" :

Certificate of Mailing Under 37 CFR §1.8(a)  
I hereby certify that this Correspondence is being deposited on  
August 19, 2004 with the United States Postal Service as first-class mail  
in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box  
1450, Alexandria, VA 22313-1450.

Janice M. Nightlinger  
Janice M. Nightlinger

REQUEST FOR LISTING OF REFERENCES

Applicant in the above-identified application is  
submitting herewith a Form PTO-1449 listing references that  
were considered and made of record in connection with  
Applicants' parent U.S. Application No. 09/870,379, filed  
May 30, 2001.

It is respectfully requested that the references included  
in the Form PTO-1449 submitted herewith be listed on the face  
of the patent granted on the above-identified application, in  
accordance with the following provisions of §609 of the Manual  
of Patent Examining Procedure:

[T]he examiner will consider information which has  
been considered by the Office in a parent application  
when examining (A) a continuation application filed  
under 37 CFR 1.53(b) or filed under former 37 CFR  
160, (B) a divisional application filed under 37 CFR  
1.53(b) or filed under form 37 CFR 1.60, or (C) a  
continuation-in-part application filed under 37 CFR  
1.53(b). Such information need not be resubmitted in  
the continuing application unless applicant desires  
the information to be printed on the patent.

In the event any fee is due in connection with the consideration of this request, the Commissioner is authorized to charge any such fee to the account of the undersigned attorneys, Deposit Account No. 04-1406.


Respectfully submitted,

DANN DORFMAN HERRELL and  
SKILLMAN, P.C.  
Attorneys for Applicant

By Kathleen D. Rigaut  
Kathleen D. Rigaut, Ph.D., J.D.  
Registration No. 43,047

KDR:jmn  
Enclosure

Telephone: 215-563-4100  
Facsimile: 215-563-4044  
Customer No. 000110



# INFORMATION DISCLOSURE STATEMENT

SHEET 1 OF 1

*Complete if known*

Application Number: 09/870379

Filing Date: May 30, 2001

First Named Inventor: Donald L. Durden

Group Art Unit: 1642

Examiner Name: Yu, Misook

Attorney Docket Number: 1857-P02575US1

## UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	6020199	02-01-2000	Monia, et al.

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

## OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	LI, DA-MING, et al., "PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G <sub>1</sub> cell cycle arrest in human glioblastoma cells"; Proc. Natl. Acad. Sci. USA, 95:15406-15411 (1998)
	C2	LI, LIWU, et al., "A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast"; J. Biological Chemistry, 272: 29403-29406 (1997)
	C3	LI, JING, et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer"; Science 275: 1943-1947 (1997)
	C4	HUANG, HE, et al., "PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development"; Development 126: 5365-5372 (1999)
	C5	LEE, JIE-OH, et al., "Crystal Structure of the PTEN Tumor Suppressor: Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association"; Cell, 99: 323-334 (1999)
	C6	SUN, HONG, et al., "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway"; Proc. Natl. Acad. Sci. USA 96: 6199-6204 (1999)
	C7	GIRI, D., et al., "Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma"; PubMed, Hum. Pathol. 30:419-24 [abstract] (1999)

EXAMINER'S SIGNATURE		DATE CONSIDERED	
----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of :  
Donald L. Durden : Examiner: Not Yet Assigned  
: Group Art Unit: 1641  
Serial No. 10/770,725 :  
:  
:  
Filed: February 3, 2004 :  
:  
For: "COMPOSITIONS AND METHODS:  
FOR IDENTIFYING AGENTS :  
WHICH MODULATE PTEN :  
FUNCTION AND PI-3 KINASE :  
PATHWAYS" :  
:

Certificate of Mailing Under 37 CFR §1.8(a)  
I hereby certify that this Correspondence is being deposited on  
August 19, 2004 with the United States Postal Service as first-class mail  
in an envelope properly addressed to COMMISSIONER FOR PATENTS, P.O. Box  
1450, Alexandria, VA 22313-1450.

Janice M. Nightlinger  
Janice M. Nightlinger

REQUEST FOR LISTING OF REFERENCES

Applicant in the above-identified application is  
submitting herewith a Form PTO-1449 listing references that  
were considered and made of record in connection with  
Applicants' parent U.S. Application No. 09/870,379, filed  
May 30, 2001.


It is respectfully requested that the references included  
in the Form PTO-1449 submitted herewith be listed on the face  
of the patent granted on the above-identified application, in  
accordance with the following provisions of §609 of the Manual  
of Patent Examining Procedure:

[T]he examiner will consider information which has  
been considered by the Office in a parent application  
when examining (A) a continuation application filed  
under 37 CFR 1.53(b) or filed under former 37 CFR  
160, (B) a divisional application filed under 37 CFR  
1.53(b) or filed under form 37 CFR 1.60, or (C) a  
continuation-in-part application filed under 37 CFR  
1.53(b). Such information need not be resubmitted in  
the continuing application unless applicant desires  
the information to be printed on the patent.

In the event any fee is due in connection with the consideration of this request, the Commissioner is authorized to charge any such fee to the account of the undersigned attorneys, Deposit Account No. 04-1406.


Respectfully submitted,

DANN DORFMAN HERRELL and  
SKILLMAN, P.C.  
Attorneys for Applicant

By   
Kathleen D. Rigaut, Ph.D., J.D.  
Registration No. 43,047

KDR:jmn  
Enclosure

Telephone: 215-563-4100  
Facsimile: 215-563-4044  
Customer No. 000110



**INFORMATION  
DISCLOSURE  
STATEMENT**

SEARCHED

INDEXED

MAILED

*Complete if known*

Application Number: 09/870379

Filing Date: May 30, 2001

First Named Inventor: Donald L. Durden

Group Art Unit: 1642

Examiner Name: Yu, Misook

SHEET 1 OF 1

Attorney Docket Number: 1857-P02575US1

**UNITED STATES PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	6020199	02-01-2000	Monia, et al.

**FOREIGN PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

**OTHER PRIOR ART - NON-PATENT DOCUMENTS**

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	LI, DA-MING, et al., "PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G <sub>1</sub> cell cycle arrest in human glioblastoma cells"; Proc. Natl. Acad. Sci. USA, 95:15406-15411 (1998)
	C2	LI, LIWU, et al., "A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast"; J. Biological Chemistry, 272: 29403-29406 (1997)
	C3	LI, JING, et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer"; Science 275: 1943-1947 (1997)
	C4	HUANG, HE, et al., "PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development"; Development 126: 5365-5372 (1999)
	C5	LEE, JIE-OH, et al., "Crystal Structure of the PTEN Tumor Suppressor: Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association"; Cell, 99: 323-334 (1999)
	C6	SUN, HONG, et al., "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5 -trisphosphate and Akt/protein kinase B signaling pathway"; Proc. Natl. Acad. Sci. USA 96: 6199-6204 (1999)
	C7	GIRI, D., et al., "Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma"; PubMed, Hum. Pathol. 30:419-24 [abstract] (1999)

EXAMINER'S SIGNATURE		DATE CONSIDERED
----------------------	--	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.